Oltef-VG Vaginal Gel contains Clotrimazole 2% w/w, an imidazole antifungal agent indicated for the treatment of vulvovaginal candidiasis caused by susceptible strains of Candida species. Clotrimazole acts by inhibiting the biosynthesis of ergosterol, an essential component of fungal cell membranes, leading to increased membrane permeability and ultimately fungal cell death. Oltef-VG Vaginal Gel is formulated for intravaginal application, providing localized antifungal activity with minimal systemic absorption. It is typically administered once daily at bedtime for a duration of 3 to 7 days, depending on the severity of infection and clinical response. The gel base ensures uniform distribution and prolonged contact with the vaginal mucosa, enhancing therapeutic efficacy. Oltef-VG is generally well tolerated; however, mild local irritation, burning, or itching may occur. Contraindications include hypersensitivity to clotrimazole or any component of the formulation. Caution is advised in pregnant or lactating women; use only if clearly needed and under medical supervision. Patients should avoid sexual intercourse during treatment to prevent transmission and reinfection. Oltef-VG Vaginal Gel offers an effective and convenient option for the management of vulvovaginal candidiasis, promoting symptomatic relief and resolution of infection.